Edition:
India

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

4.52EUR
7:38pm IST
Change (% chg)

€-0.05 (-1.01%)
Prev Close
€4.57
Open
€4.59
Day's High
€4.59
Day's Low
€4.51
Volume
34,441
Avg. Vol
150,723
52-wk High
€11.40
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN

* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN

18 Apr 2018

BRIEF-Reg-Innate Pharma Aacr 2018, New Preclinical Data Further Support Ongoing Programs

* REG-INNATE PHARMA : AACR 2018, NEW PRECLINICAL DATA FURTHER SUPPORT ONGOING PROGRAMS Source text for Eikon: Further company coverage:

17 Apr 2018

BRIEF-Innate Pharma Announces Its Partner Medimmune Expands Colorectal Cancer Patient Cohort In A Phase I Trial

* INNATE PHARMA SA - PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Mar 2018

BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi

* REG-INNATE PHARMA : EXPANSION OF MCRC COHORT IN PHASE I TRIAL EVALUATING MONALIZUMAB WITH IMFINZI

23 Mar 2018

BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros

* FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO

08 Mar 2018

Earnings vs. Estimates